The Top 5 Analyst Questions From Myriad Genetics’s Q3 Earnings Call

2 weeks ago 10

Petr Huřťák

Sun, November 9, 2025 astatine 11:31 PM CST 4 min read

Myriad Genetics’ 3rd 4th saw gross and adjusted nett successful enactment with Wall Street expectations, but the marketplace reacted negatively owed to ongoing challenges successful mean gross per trial and operational headwinds. Management cited continued beardown measurement maturation successful the oncology segment, peculiarly for its MyRisk hereditary crab test, arsenic a positive. CEO Samraat Raha noted, “MyRisk continues to spot affirmative request successful the marketplace and supports our profitable maturation journey,” portion besides acknowledging the interaction of payer premix and argumentation changes. The institution faced unit from reduced sum for its GeneSight intelligence wellness trial and a divested European business, but highlighted improved execution and stabilization successful halfway trial volumes.

Is present the clip to bargain MYGN? Find retired successful our afloat probe study (it’s escaped for progressive Edge members).

Revenue: $205.7 cardinal vs expert estimates of $204.8 cardinal (3.6% year-on-year decline, successful line)
Adjusted EPS: $0 vs expert estimates of -$0.01 ($0.01 beat)
Adjusted EBITDA: $10.3 cardinal vs expert estimates of $5.57 cardinal (5% margin, 84.8% beat)
The institution reconfirmed its gross guidance for the afloat year of $823 cardinal astatine the midpoint
EBITDA guidance for the afloat year is $30 cardinal astatine the midpoint, supra expert estimates of $27.52 million
Operating Margin: -11.3%, down from -9.4% successful the aforesaid 4th past year
Market Capitalization: $587.2 million

While we bask listening to the management's commentary, our favourite portion of net calls are the expert questions. Those are unscripted and tin often item topics that absorption teams would alternatively debar oregon topics wherever the reply is complicated. Here is what has caught our attention.

Puneet Souda (Leerink Partners) asked astir balancing commercialized concern with profitability. CEO Samraat Raha and CFO Ben Wheeler reiterated that organizational redesign volition money maturation successful crab attraction portion maintaining a absorption connected nett improvement.
David Westenberg (TD Cowen) inquired astir prenatal marketplace stock and operational improvements. Raha explained that portion prenatal volumes were flat, lawsuit losses from earlier operational issues are being addressed, and FirstGene is expected to enactment aboriginal growth.
Kyle Boucher (TD Cowen) questioned whether hereditary crab investigating measurement maturation was owed to catch-up from anterior workflow issues. Raha clarified improvements came from amended lawsuit workflows and EMR integration, not a impermanent rebound.
Lauren Timmins (Jefferies) sought clarification connected mean selling terms declines successful hereditary crab tests and aboriginal KPIs. CFO Ben Wheeler cited payer mix, biopharma gross lumpiness, and UnitedHealthcare’s argumentation arsenic superior ASP drivers, portion Mark Verratti highlighted plans to way expanded supplier basal and multi-product adoption.
Ricki Levitus (Guggenheim) asked astir turnaround times for Prequel and FirstGene. COO Mark Verratti confirmed some tests connection competitory turnaround times, with FirstGene expected to align with Prequel astatine launch.